Is Zydus Lifesciences (ZYDUSLIFE) overvalued or fairly valued?

MarketChacha shows Zydus Lifesciences's valuation in context — a forward P/E of about 22.6, a price-to-book of about 4.1 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Zydus Lifesciences's revenue?

Zydus Lifesciences reported revenue of ₹11,484 Cr for FY2026, with net profit of ₹3,560 Cr, per official filings.

What is the share price of Zydus Lifesciences (ZYDUSLIFE)?

Zydus Lifesciences last traded at ₹1,113.90 (-2.3% on the day), as of 10/19/2026 — a delayed quote shown for education, not investment advice.

Zydus Lifesciences

ZYDUSLIFE · NSE · Pharma · India

Snapshot

TickerZYDUSLIFE

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees29,980

HeadquartersAhmedabad, India

Websitezyduslife.com

Filings tracked19

About Zydus Lifesciences

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Consumer Products, and Medical Technologies. The company offers active pharmaceutical ingredients, human and finished dosage formulations, generics, branded generics, specialty formulations, biosimilars, vaccines, novel therapeutics, medical devices and technologies, consumer wellness, veterinary, and animal health products. It also provides biological products in the areas of oncology, autoimmune disorders, nephrology, inflammation, rheumatology, hepatology, and infectious diseases; and designs and executes clinical trials across new chemical entities (NCEs), biologics, vaccines, and specialty generics. In addition, the company operates seasonal, skin and healthcare, and food and nutrition products under the Glucon D, Complan, Sugar Free, Nycil, Everyuth, Nutralite, and RiteBite Max Protein brands. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Who owns it

Promoters75.2%
Institutions15.5%
Public & other9.4%

176 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend11.4% → 18.6%

Margin has expanded by about 7.2 points — the business is getting more profitable.

Growth qualityrev 12% · PAT 27%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹7,936 Cr · EPS 8.70

Est. earnings growth -20.6%

Next fiscal year

Rev ₹35,224 Cr · EPS 49.31

Est. earnings growth +22.2%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 5

Revenue (FY2026)

₹27,148 Cr

Net margin

18.6%

Revenue CAGR (3y)

+16.3%

Profit CAGR (3y)

+37.0%

Net profit (FY2026)

₹5,040 Cr

Ask MarketChacha about ZYDUSLIFE

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹27,148 Cr	₹5,040 Cr	18.6%
FY2025	₹23,242 Cr	₹4,526 Cr	19.5%
FY2024	₹19,547 Cr	₹3,860 Cr	19.7%
FY2023	₹17,237 Cr	₹1,960 Cr	11.4%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
Q1 FY27	₹8,017 Cr	₹990 Cr	9.35	12.4%
Q4 FY26	₹7,587 Cr	₹1,341 Cr*	12.65	17.7%
Q3 FY26	₹6,865 Cr	₹1,042 Cr	—	15.2%
Q2 FY26	₹6,123 Cr	₹1,259 Cr	—	20.6%
Q1 FY26	₹6,574 Cr	₹1,467 Cr	—	22.3%

* Net profit includes one-off / non-operating items (e.g. a settlement or accounting gain), so it doesn’t reflect operating performance — net margin is hidden for that period.

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Press Release / Media Release
Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Saroglitazar Mg in MASH.
BSE8/31/2026
Incorporation Of A Wholly Owned Subsidiary In Gift City, Gandhinagar, Gujarat
Incorporation of a wholly owned subsidiary in Gift City, Gandhinagar, Gujarat
BSE8/26/2026
Disclosure Under SEBI (Prohibition Of Insider Trading) Regulations, 2015
Disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015
BSE8/24/2026
Investor Presentation
Investor Presentation
BSE8/23/2026
ESG Rating
ESG Rating
BSE8/21/2026
Press Release / Media Release
Zydus announces final approval from the USFDA for Ascorbic Acid Injection with 180-Days CGT exclusivity.
BSE8/21/2026
Shareholder Meeting / Postal Ballot-Outcome of AGM
Regulation 44(3) disclosure of AGM 2026
BSE8/11/2026material
Change in Directorate
Change in Directors
BSE8/11/2026
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Scrutinizer''s report
BSE8/11/2026material
Shareholder Meeting / Postal Ballot-Outcome of AGM
Outcome of AGM
BSE8/11/2026material
Reporting Of Violation Of Code Of Conduct Under SEBI (Prohibition Of Insider Trading) Regulations, 2015
Reporting of violation of Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations, 2015
BSE8/11/2026
Press Release / Media Release
Press Release
BSE8/11/2026
Press Release / Media Release
Press Release
BSE8/11/2026
Investor Presentation
Investor Presentation
BSE8/11/2026
Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended On June 30, 2026
Unaudited financial results for the quarter ended on June 30, 2026
BSE8/11/2026
Unaudited Financial Results For The Quarter Ended On June 30, 2026
Unaudited financial results for the quarter ended on June 30, 2026
BSE8/11/2026
Receipt Of Order From The Office Of The Superintendent Of Stamps, Gandhinagar, Gujarat
Receipt of order from the Office of the Superintendent of Stamps, Gandhinagar, Gujarat.
BSE7/29/2026
Strikes /Lockouts / Disturbances
Disruption of operations due to heavy rain and water logging
BSE7/25/2026
Press Release / Media Release
Zydus receives approval for Phase III trial of Desidustat in patients with Sickle Cell Disease, to be conducted in collaboration with ICMR.
BSE7/23/2026

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.